clinical trial · NCT00648297
Fed Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg
HealthyNadolol/Bendroflumethiazide Tablets 80 mg/5 mgCorzide® Tablets 80 mg/5 mg
brief summary
The objective of this study was to investigate the bioequivalence of Mylan's nadolol/bendroflumethiazide 80 mg/5 mg tablets to King's Corzide® 80 mg/5 mg tablets following a single, oral 80 mg/5 mg (1 x 80 mg/5 mg) dose administered under fed conditions.
started
Aug 1, 2006
primary completion
Aug 1, 2006
completion
Aug 1, 2006
last updated
Apr 23, 2024
official title
Single-Dose Fed Bioequivalence Study of Nadolol/Bendroflumethiazide Tablets (80 mg/5 mg; Mylan) and Corzide® Tablets (80 mg/5 mg; King) in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol